BusinessBiogen Revenue Climbs 11% as Growth Portfolio Revenue Jumps 49%By Helena WardOct 28, 2026, 12:04 PM UTC
BusinessINVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKSBy Nasdaq OMXDec 13, 2017, 6:13 PM UTC
BusinessStreetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug CandidateBy Nasdaq OMXNov 23, 2017, 1:45 PM UTC
